Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology
Author:
Affiliation:
1. Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy
2. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Abstract
Publisher
American Medical Association (AMA)
Link
https://jamanetwork.com/journals/jamaoncology/articlepdf/2816343/jamaoncology_trapani_2024_vp_240001_1715802185.35131.pdf
Reference7 articles.
1. HER2-low breast cancer-diagnostic challenges and opportunities for insights from ongoing studies: a podcast.;Bardia;Target Oncol,2023
2. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial.;Yamaguchi;J Clin Oncol,2023
3. Biomarker data from the phase III KATHERINE study of adjuvant T-DM1 versus trastuzumab for residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.;Denkert;Clin Cancer Res,2023
4. Trop-2 as a therapeutic target in breast cancer.;Sakach;Cancers (Basel),2022
5. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.;Gilbert;Gynecol Oncol,2023
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Beyond Cytotoxic Potency: Disposition Features Required to Design ADC Payload;Xenobiotica;2024-07-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3